Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan

Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl peptidase 4 inhibitors may be associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Wei-Hao, Sue, Shu-Ping, Liang, Hsiu-Ling, Tseng, Chin-Wei, Lin, Hsiu-Chu, Wen, Wei-Lun, Lee, Mei-Yueh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484707/
https://www.ncbi.nlm.nih.gov/pubmed/34604157
http://dx.doi.org/10.3389/fpubh.2021.711723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484707/
https://www.ncbi.nlm.nih.gov/pubmed/34604157
http://dx.doi.org/10.3389/fpubh.2021.711723

Ejemplares similares